Partisan politics may be holding up the impending M&A deal between Walgreens Boots Alliance Inc (NASDAQ:
WBA) and Rite Aid Corporation (NYSE:
RAD), Deutsche Bank said in a note earlier this week.
Walgreens may try to force a Federal Trade Commission decision on the deal within 30 days, analysts George Hill and Stephen
Hagan said. Why does this matter? The traditionally five-member FTC board has three vacant seats.
The commissioner, a Democrat, may oppose the deal, and the chairperson, a Republican, is unlikely to vote against the deal, the
analysts said.
Deutsche highlighted reports that suggested Walgreens could certify it has complied with the second request and force
short-staffed FTC to make a decision. Media reports indicate the regulatory agency still has issues with the
deal and with Fred's, Inc. (NASDAQ: FRED)
as a buyer, Deutsche Bank said.
See Also: A
Positive View On Walgreens Doesn't Depend On Rite Aid Deal
Downside If Deal Fails
Deutsche Bank feels the downside to Walgreens is in the range of $73-$79 if the deal fails to close. This range, according to
the firm, represents 14 to 15 times its calendar year 2017 earnings per share estimate of $5.24. Additionally, the firm said the
range represents the current pharma services average to a one-turn premium, which the analysts feel is justifiable, given
Walgreens' positive operating leverage and capital deployment flexibility, excluding a deal for Rite Aid.
If the deal falls through, Rite Aid shares could drop from $4.71 to $2.25, the firm said. The $2.25 stock price estimate is
based on an EV/EBITDA multiple of eight times its calendar year 2017 estimates, with the multiple representing a "slight discount"
from where Walgreens and CVS Health Corp (NYSE: CVS) trade. This multiple, Deutsche Bank said, is fair for a subscale player in the
competitive retail pharmacy space.
Deutsche Bank has a Buy rating on Walgreens with a $92 price target.
Image:
Mike Mozart, Flickr
Latest Ratings for WBA
Date |
Firm |
Action |
From |
To |
Oct 2016 |
Wells Fargo |
Initiates Coverage On |
|
Outperform |
Oct 2016 |
Jefferies |
Upgrades |
Hold |
Buy |
Oct 2016 |
UBS |
Initiates Coverage on |
|
Buy |
View More Analyst Ratings for
WBA
View the Latest Analyst Ratings
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.